Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD,

Slides:

Advertisements

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Advertisements

The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes

William B. White, MD, Robert A. Hauser, MD, MBA, Gerald J

Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia Pablo Lázaro, MD, PhD, MBA, Leopoldo Pérez.

Effects of 2 Different Doses of Pregabalin on Morphine Consumption and Pain After Abdominal Hysterectomy: A Randomized, Double-Blind Clinical Trial Aytaç.

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

Characterization of Abdominal Pain During Methylnaltrexone Treatment of Opioid- Induced Constipation in Advanced Illness: A Post Hoc Analysis of Two Clinical.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C- III levels in patients from the MARINE and ANCHOR studies Christie.

Predictors of first-year statin medication discontinuation: A cohort study Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

% decrease in LDL-C at 24 weeks from baseline

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche, PhD,

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

A Randomized, Double-Blind, Placebo-Controlled Trial of Nutritional Supplementation During Acute Illness Salah Gariballa, MD, Sarah Forster, MSc, Stephen.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Temporal Trends in Lipid Screening for Familial Hypercholesterolemia in Youth Catherine J. McNeal, MD, PhD, Justin Zachariah, MD, MPH, Laurel Copeland,

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Temporal Trends in Lipid Screening for Familial Hypercholesterolemia in Youth Catherine J. McNeal, MD, PhD, Justin Zachariah, MD, MPH, Laurel Copeland,

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

Comparative effects of an acute dose of fish oil on omega-3 fatty acid levels in red blood cells versus plasma: Implications for clinical utility William.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

An assessment by the Statin Intolerance Panel: 2014 update

Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a)

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.

Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia Andrew G. Bostom,

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment Robert Dufour,

The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study Michael Davidson, MD, Michael Stevenson, RPh, PhD, Andrew Hsieh,

Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT.

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia Frederick J. Raal, PhD, Marjet J. Braamskamp,

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design Dirk J. Blom, MD, PhD, Zahi A. Fayad,

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Presentation transcript:

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD, PhD, MBA, John R. Guyton, MD, Gisle Langslet, MD, Robert Dufour, MD, MSc, CSPQ, Marie T. Baccara-Dinet, MD, MSc, Chantal Din-Bell, MSc, Garen Manvelian, MD, Michel Farnier, MD, PhD Journal of Clinical Lipidology Volume 12, Issue 6, Pages 1463-1470 (November 2018) DOI: 10.1016/j.jacl.2018.08.011 Copyright © 2018 National Lipid Association Terms and Conditions

Journal of Clinical Lipidology 2018 12, 1463-1470DOI: (10.1016/j.jacl.2018.08.011) Copyright © 2018 National Lipid Association Terms and Conditions

Figure 1 OLE study design. †Patients enrolled from HIGH FH were not included in this analysis as they started OLE on alirocumab 150 mg Q2W, with no dose adjustment during the study duration. ‡To be performed 2 weeks after the last injection for the patients who completed the study or within 5 days after treatment discontinuation. §To be performed 10 weeks after the last injection. During the double-blind treatment period of FH I and FH II, patients received alirocumab 75 mg or 150 mg Q2W or placebo. During the double-blind treatment period of LONG TERM and HIGH FH, patients received alirocumab 150 mg Q2W or placebo. Patients who completed FH I, FH II, and LONG TERM started OLE with alirocumab 75 mg Q2W, which could be increased to 150 mg Q2W after week 12. Patients from HIGH FH began OLE with alirocumab 150 mg Q2W (but were not included in the present analysis). HeFH, heterozygous familial hypercholesterolemia; LLT, lipid-lowering therapy; NCEP ATP III TLC, National Cholesterol Education Program Adult Treatment Panel III Therapeutic Lifestyle Changes; OLE, open-label extension; Q2W, every 2 weeks; W, week. Journal of Clinical Lipidology 2018 12, 1463-1470DOI: (10.1016/j.jacl.2018.08.011) Copyright © 2018 National Lipid Association Terms and Conditions